Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model
暂无分享,去创建一个
Ho-Chul Shin | Lawrence X. Yu | Duxin Sun | Ho-Chul Shin | G. Amidon | Duxin Sun | Xianhua Cao | Yanqiang Zhong | Gordon L. Amidon | Yan-qiang Zhong | Xianhua Cao | Hans Lennernas | Lawrence X. Yu | Seth T. Gibbs | Lanyan Fang | Heather A. Miller | Christopher P. Landowski | C. Landowski | H. Lennernas | Lanyan Fang | S. Gibbs | Heather A. Miller | Gordon L. Amidon
[1] Paul W. Buehler,et al. Comparison of Oral Absorption and Bioavailability of Drugs Between Monkey and Human , 2002, Pharmaceutical Research.
[2] K. Takara,et al. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[3] B. H. Migdalof,et al. Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases , 1988, Clinical pharmacokinetics.
[4] Y. Sugiyama,et al. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3) 1 , 1998 .
[5] D. Smith,et al. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. , 1998, British journal of clinical pharmacology.
[6] W Krause,et al. Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences. , 1983, Drug metabolism and disposition: the biological fate of chemicals.
[7] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[8] T. Baillie,et al. Is the role of the small intestine in first-pass metabolism overemphasized? , 1999, Pharmacological reviews.
[9] Hans Lennernäs,et al. Comparison Between Permeability Coefficients in Rat and Human Jejunum , 1996, Pharmaceutical Research.
[10] J. M. Shaw,et al. Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. , 1981, Journal of pharmaceutical sciences.
[11] H Lennernäs,et al. Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.
[12] S. Takenoshita,et al. Immuno-localization of H+/peptide cotransporter in rat digestive tract. , 1996, Biochemical and biophysical research communications.
[13] K. Terada,et al. Interaction of tri-O-methyl-beta-cyclodextrin with drugs. II. Enhanced bioavailability of ketoprofen in rats when administered with tri-O-methyl-beta-cyclodextrin. , 1983, Chemical & pharmaceutical bulletin.
[14] H Lennernäs,et al. Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag. , 1999, Acta physiologica Scandinavica.
[15] M. Iwaki,et al. Bioavailability of indomethacin calcium and magnesium, and effect of the salts on drug metabolizing enzyme activities in rats. , 1983, Journal of pharmacobio-dynamics.
[16] S. Pond,et al. First-Pass Elimination Basic Concepts and Clinical Consequences , 1984, Clinical pharmacokinetics.
[17] J. Young,et al. STUDIES ON THE ABSORPTION, METABOLISM AND EXCRETION OF METHYLDOPA AND OTHER CATECHOLS AND THEIR INFLUENCE ON AMINO ACID TRANSPORT IN RATS. , 1964, The Journal of pharmacology and experimental therapeutics.
[18] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[19] R. Kapil,et al. Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. , 1984, Journal of pharmaceutical sciences.
[20] M. Kasuga,et al. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[21] Patrick J. Sinko,et al. Predicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach , 1991, Pharmaceutical Research.
[22] J. Kolars,et al. CYP3A gene expression in human gut epithelium. , 1994, Pharmacogenetics.
[23] H. Lennernäs,et al. The Influence of Net Water Absorption on the Permeability of Antipyrine and Levodopa in the Human Jejunum , 1994, Pharmaceutical Research.
[24] Mort Rosenberg,et al. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Edition. , 2003 .
[25] M. Hussain,et al. Buccal and oral bioavailability of nalbuphine in rats. , 1986, Journal of pharmaceutical sciences.
[26] C. Beglinger,et al. MAPPING OF MULTIDRUG RESISTANCE GENE 1 AND MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN ISOFORM 1 TO 5 mRNA EXPRESSION ALONG THE HUMAN INTESTINAL TRACT , 2005, Drug Metabolism and Disposition.
[27] Y. Sugiyama,et al. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. , 2002, American journal of physiology. Gastrointestinal and liver physiology.
[28] L. F. Chasseaud,et al. Isosorbide 5‐mononitrate kinetics , 1984, Clinical pharmacology and therapeutics.
[29] G. Castañeda-Hernández,et al. Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat. , 1999, Canadian journal of physiology and pharmacology.
[30] S. Connolly,et al. Clinical Pharmacokinetics of N-acetylprocainamide , 1982, Clinical pharmacokinetics.
[31] R. Mehvar,et al. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. , 1987, Drug metabolism and disposition: the biological fate of chemicals.
[32] K. C. Kwan,et al. Pharmacokinetics of methyldopa in man. , 1976, The Journal of pharmacology and experimental therapeutics.
[33] F. Jamali,et al. Clinical Pharmacokinetics of Ketoprofen and Its Enantiomers , 1990, Clinical pharmacokinetics.
[34] D. Richards. Comparative Pharmacodynamics and Pharmacokinetics of Cimetidine and Ranitidine , 1983, Journal of clinical gastroenterology.
[35] H. Lennernäs,et al. Rat Jejunal Permeability and Metabolism of μ-Selective Tetrapeptides in Gastrointestinal Fluids from Humans and Rats , 1997, Pharmaceutical Research.
[36] K. Fotherby. Levonorgestrel. Clinical pharmacokinetics. , 1995, Clinical pharmacokinetics.
[37] R. Foster,et al. PHARMACOKINETICS OF THE ENANTIOMERS OF VERAPAMIL AFTER INTRAVENOUS AND ORAL ADMINISTRATION OF RACEMIC VERAPAMIL IN A RAT MODEL , 1997, Biopharmaceutics & drug disposition.
[38] Anne Hersey,et al. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. , 2003, European journal of medicinal chemistry.
[39] M. Manns,et al. Polymorphic Gene Regulation and Interindividual Variation of UDP-glucuronosyltransferase Activity in Human Small Intestine* , 2000, The Journal of Biological Chemistry.
[40] D. Keppler,et al. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. , 1997, The Biochemical journal.
[41] H. Lennernäs,et al. The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. , 1995, Journal of drug targeting.
[42] J. Noordhoek,et al. Distribution of glucuronidation capacity (1-naphthol and morphine) along the rat intestine. , 1985, Biochemical pharmacology.
[43] D. McTavish,et al. Verapamil , 2012, Drugs.
[44] P. Fagiolino,et al. Bioavailability study of furosemide prodrugs in rats. , 1992, Farmaco.
[45] W. L. Chiou. The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats. , 1995, Biopharmaceutics & drug disposition.
[46] J. Reid,et al. The metabolism and kinetics of doxazosin in man, mouse, rat and dog. , 1986, British journal of clinical pharmacology.
[47] M. Hayashi,et al. A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[48] H. Lennernäs,et al. Regional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man , 1995, Pharmaceutical Research.
[49] S. Nylander,et al. Jejunal Permeability: A Comparison Between the Ussing Chamber Technique and the Single-Pass Perfusion in Humans , 1997, Pharmaceutical Research.
[50] D. Dunbar,et al. Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[51] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[52] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[53] B. Steffansen,et al. Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[54] L. Benet,et al. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. , 2002, The Journal of pharmacology and experimental therapeutics.
[55] G. Amidon,et al. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. , 2002, Journal of pharmaceutical sciences.
[56] G. Amidon,et al. Intestinal absorption of amino acid derivatives: importance of the free alpha-amino group. , 1982, Journal of pharmaceutical sciences.
[57] M. Hümpel,et al. Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys☆ , 1981 .
[58] J. Kolars,et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.
[59] H. Lennernäs,et al. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. , 1999, British journal of clinical pharmacology.
[60] C. Beglinger,et al. Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation , 1996, British journal of pharmacology.
[61] G. Amidon,et al. Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. , 2001, Journal of Pharmacology and Experimental Therapeutics.
[62] Lawrence X. Yu,et al. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. , 2004, Current opinion in drug discovery & development.
[63] P. Beaune,et al. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. , 1990, The Journal of pharmacology and experimental therapeutics.
[64] M. Mattila,et al. Pharmacokinetics of Oxicam Nonsteroidal Anti-Inflammatory Agents , 1994, Clinical pharmacokinetics.
[65] G. Amidon,et al. Human Jejunal Permeability of Two Polar Drugs: Cimetidine and Ranitidine , 2001, Pharmaceutical Research.
[66] W. Rubas,et al. Comparison of the Permeability Characteristics of a Human Colonic Epithelial (Caco-2) Cell Line to Colon of Rabbit, Monkey, and Dog Intestine and Human Drug Absorption , 2004, Pharmaceutical Research.
[67] P. Brooks,et al. Clinical Pharmacokinetics of the Salicylates , 1985, Clinical pharmacokinetics.
[68] S. Adibi. The oligopeptide transporter (Pept-1) in human intestine: biology and function. , 1997, Gastroenterology.
[69] Gordon L. Amidon,et al. Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.
[70] Y. Sugiyama,et al. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). , 1998, FEBS letters.
[71] H Lennernäs,et al. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.
[72] C. Rozé,et al. Chronic nifedipine dosing enhances cephalexin bioavailability and intestinal absorption in conscious rats. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[73] Hans Lennernäs,et al. Jejunal Absorption and Metabolism of R/S-Verapamil in Humans , 1998, Pharmaceutical Research.
[74] A. Barve,et al. Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats , 1998, Pharmaceutical Research.
[75] G. Amidon,et al. Human Intestinal Permeability of Piroxicam, Propranolol, Phenylalanine, and PEG 400 Determined by Jejunal Perfusion , 1997, Pharmaceutical Research.
[76] G. Amidon,et al. Gene Expression in the Human Intestine and Correlation with Oral Valacyclovir Pharmacokinetic Parameters , 2003, Journal of Pharmacology and Experimental Therapeutics.
[77] M. Holdiness,et al. Clinical Pharmacokinetics of the Antituberculosis Drugs , 1984, Clinical pharmacokinetics.
[78] G. Amidon,et al. Passive and Carrier-Mediated Intestinal Absorption Components of Two Angiotensin Converting Enzyme (ACE) Inhibitor Prodrugs in Rats: Enalapril and Fosinopril , 1989, Pharmaceutical Research.